Physician

Shalin Ramesh Shah, D.O.

According to 2025 Medicare claims, Shalin Shah, D.O. (NPI: 1265591804) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33511-4307. Shah is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 821 traditional Medicare patients, billed 293,772 HCPCS/CPT codes, and received $4,349,501 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,494 prescription claims across 300 beneficiaries totaling $5,778,118 in drug costs, led by Revlimid (Lenalidomide). DME data shows 61 claims. Open Payments data shows 114 records totaling $3,414. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,117,630 to $5,778,118. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,072	338,290	$3,321,069
2016	1,023	370,313	$3,899,113
2017	1,101	454,571	$4,411,093
2018	1,116	401,919	$4,495,243
2019	1,216	398,768	$4,675,248
2020	1,122	445,806	$4,524,818
2021	958	312,326	$4,154,215
2022	964	319,071	$3,612,269
2023	918	383,165	$5,352,878
2024	821	293,772	$4,349,501

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	214	1,078	$1,117,630
2016	229	1,041	$1,961,452
2017	235	1,084	$2,171,838
2018	278	1,176	$2,625,160
2019	300	1,350	$2,892,847
2020	306	1,406	$4,160,102
2021	325	1,377	$4,316,210
2022	327	1,450	$4,149,871
2023	297	1,322	$5,114,803
2024	300	1,494	$5,778,118

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	143	$6,563
2016	N/R	120	$23,481
2017	N/R	127	$36,456
2018	N/R	125	$15,920
2019	N/R	187	$33,489
2020	N/R	79	$7,421
2021	N/R	71	$5,428
2022	N/R	79	$3,099
2023	N/R	53	$5,658
2024	N/R	61	$1,254

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	546	1,520	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	177	240	$64
96372	Injection of drug or substance under skin or into muscle	189	800	$11
36415	Insertion of needle into vein for collection of blood sample	646	2,290	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	659	2,497	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	98	2,513	$1,538,057
Jakafi	Ruxolitinib Phosphate	33	990	$652,129
Ibrance	Palbociclib	29	812	$439,457
Lenvima	Lenvatinib Mesylate	13	390	$317,247
Verzenio	Abemaciclib	18	504	$255,340

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$556
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$514
J8520	Capecitabine, oral, 150 mg	N	N/R	17	$183

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	114	$3,414	Biosense Webster, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shalin Ramesh Shah, D.O.?

Tedicare shows public-source Medicare data for Shalin Ramesh Shah, D.O. (NPI 1265591804), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shalin Ramesh Shah, D.O. have ACO affiliation data?

Shalin Ramesh Shah, D.O. is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Shalin Ramesh Shah, D.O.?

Shalin Ramesh Shah, D.O. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Shalin Ramesh Shah, D.O. have Open Payments data?

Shalin Ramesh Shah, D.O. has 114 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.